AA
HRTX icon

ACT Advisors’s Heron Therapeutics HRTX Stock Holding History

ACT Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28,443
Closed -$22.8K – 89
2026
Q1 		$22.8K Buy
28,443
+2,635
+10% +$3.05K 0.01% 73
2025
Q4 		$33.5K Buy
25,808
+227
+0.9% +$280 0.01% 61
2025
Q3 		$32.2K Sell
25,581
-74
-0.3% -$117 0.01% 67
2025
Q2 		$53.1K Buy
25,655
+74
+0.3% +$151 0.02% 56
2025
Q1 		$56.3K Hold
25,581
– – 0.03% 53
2024
Q4 		$39.1K Hold
25,581
– – 0.02% 49
2024
Q3 		$50.9K Buy
25,581
+3,436
+16% +$8.2K 0.02% 50
2024
Q2 		$77.5K Hold
22,145
– – 0.04% 44
2024
Q1 		$61.3K Hold
22,145
– – 0.03% 43
2023
Q4 		$37.6K Buy
+22,145
New +$24.4K 0.02% 42

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

ACT Advisors's HRTX Position: Q2 2026 in Review

ACT Advisors sold out of Heron Therapeutics (HRTX) in Q2 2026, closing a stake of 28,443 shares — an estimated $22.8K sold.

ACT Advisors first reported a position in HRTX in Q4 2023 and held it in 10 quarters. The position peaked at $77.5K in Q2 2024. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • ACT Advisors reported no remaining Heron Therapeutics position as of Q2 2026 after selling out during the quarter.
  • ACT Advisors sold 28,443 Heron Therapeutics shares in Q2 2026, an estimated $22.8K.
  • ACT Advisors first reported a position in Heron Therapeutics in Q4 2023 and held it in 10 quarters.
  • ACT Advisors's Heron Therapeutics position peaked at $77.5K in Q2 2024.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on ACT Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.